NETSseq: Precision Neuroscience

Landmark discoveries for CNS disorders

NETSseq enables the identification of subtle molecular changes that can drive disease progression, offering a transformative tool to identify novel drug targets for CNS disorders.

(Nuclear Enriched Transcript Sort sequencing)

NETSseq Innovation

TARGET IDENTIFICATION

Assess targets that are circuit specific or significantly changed in disease for potential novel mechanisms of action

NETSseq Target identification process

One of the World's Largest Proprietary Brain Tissue Databases

~60

Human brain cell types under analysis that were carefully selected for their relevance to the neurological disorders being evaluated by Cerevance

>16,000

Human brain tissue samples

Control - Disease Matching

Identification of potential drug targets and pathways/curcuits most impacted in CNS diseases

92 Trillion

Base pairs sequenced

~190 TB

Data generated

Novel Genetic Support

Used in conjunction with ATACseq / eQTL that links targets to SNPs which increases the understanding of disease and helps identify novel targets of promise

Cerevance is identifying the most promising targets for the next generation of treatments for CNS disorders.

Key Publications

NETSseq Background

Species and cell-type properties of classically defined human and rodent neurons and glia

Start reading
Cerevance Therapy Targeting KCNK13

Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome

Start reading

NETSseq - Landmark discoveries for CNS disorders

Landmark discoveries for CNS disorders

NETSseq enables the identification of subtle molecular changes that can drive disease progression, offering a transformative tool to identify novel drug targets for CNS disorders.

(Nuclear Enriched Transcript Sort sequencing)

HUMAN DISEASE BIOLOGY

Identify disease-relevant human brain regions and cell types.

PURIFIED NUCLEI FROM KEY CELL TYPES

NETSseq sorts nuclei from 60+ disease relevant cell types, including ultra-rare populations.

DEEP GENOMIC AND EPIGENOMIC INSIGHTS

NETSseq enables deep transcriptomic and epigenomic profiling; largest collection of cell-type specific, multi-omics human brain data.

MACHINE LEARNING

Precise insights into disease progression of heterogenous disorders, powered by our proprietary datasets.

TARGET SELECTION

Rich pipeline of novel targets with highly specific mechanisms of action for symptomatic and disease modifying treatments.

NETSseq Innovation

TARGET IDENTIFICATION

Assess targets that are circuit specific or significantly changed in disease for potential novel mechanisms of action

One of the World's Largest Proprietary Brain Tissue Databases

~60

Human brain cell types under analysis that were carefully selected for their relevance to the neurological disorders being evaluated by Cerevance

>16,000

Human brain tissue samples

92 Trillion

Base pairs sequenced

~190 TB

Data generated

Novel Genetic Support

Used in conjunction with ATACseq / eQTL that links targets to SNPs which increases the understanding of disease and helps identify novel targets of promise

Control - Disease Matching

Identification of potential drug targets and pathways/circuits most impacted in CNS diseases

8 to 104

Donor ages across early- to late-stage CNS disease

Cerevance is identifying the most promising targets for the next generation of treatments for CNS disorders.

Key Publications

NETSseq Background

Species and cell-type properties of classically defined human and rodent neurons and glia

Start reading
Cerevance Therapy (CVN293) Targeting KCNK13

Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment

Start reading